Click here to receive MS news via e-mail
dimethyl fumarate (DMF) (aka: Tecfidera)
Post hoc data analysis of the DEFINE and CONFIRM trials showed that a higher percentage of patients with relapsing-remitting multiple sclerosis (RRMS) achieved no evidence of disease activity (NEDA) with delayed-release dimethyl fumarate (DMF) compared with placebo. The results were published in the European Journal of Neurology.1
NEDA is a relatively new composite outcome that is being used more often to measure therapeutic response in multiple sclerosis. NEDA is comprised of 3 factors: no clinical relapse, no disability progression measured by the Expanded Disability Status Scale (EDSS) for 12 weeks, and no evidence of disease activity on magnetic resonance imaging (MRI).
MS Views and News
Providing educational information, resources and services for those affected by MS, globally
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews